This $1 Healthcare Stock Just Made a Bold Move That Could Change Everything

Under-the-Radar Biotech Move Could Spark Big Momentum... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe Sponsored content from i2i Marketing Group, LLC Dear Investor, Every so often, a micro-cap stock makes a move that shifts it from under the radar to front of the line. That's exactly what just happened here. With the acquisition of a Phase 2-ready drug portfolio, this small biotech has gone from a single-asset story to a diversified pipeline company in a $38 billion global market. Why it matters: Acquisition adds both IV and oral anticoagulant candidates Lead program already carries Fast Track & Orphan Drug designations Focused on patients Big Pharma has ignored - massive unmet need Partnerships already in play with major names Lean balance sheet, multiple shots on goal, and a category-leadership strategy Micro-cap opportunities like this don't stay quiet for long. That's why it's #1 on our watchlist right now. View Ticker & Full Report

This email message is a sponsored email sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why was I sent this email message?.     We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company's SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.     If you have questions about your account, please feel free to email our U.S. based support team at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2025 MarketBeat Media, LLC. 345 N Reid Place #620, Sioux Falls, South Dakota 57103-7078. United States of America..